Current NIAID Biodefense Research Funding Opportunities
Preclinical Development
In Vitro Assessment for Antimicrobial Activity
Response Date: Jan. 22, 2010
Focus: To develop and provide in vitro assays for routine screening of products against a wide range of bacteria, fungi, viruses, parasites and toxins. In addition, this solicitation will support the development, implementation, operation, and maintenance of a central data management system to support in vitro assessment services.
Contact Info
Harry L Brubaker
E-mail: brubakerh@niaid.nih.gov
Development of Technologies to Facilitate the Use of, and Response to, Biodefense Vaccines
Response Date: Nov 18, 2009
Focus: To support the advanced development of a candidate product, which consists of a vaccine component and a delivery technology, for use in post-event settings following the intentional release of a biothreat agent or naturally occurring outbreaks of infectious diseases. In this type of setting, simplicity of operation and efficiency of delivery of the vaccine to and the effectiveness in large numbers of patients, are primary goals.
Contact Info
Timni Mahase
E-mail: mahaset@niaid.nih.gov
Partnerships for Development of Therapeutics and Diagnostics for Drug-Resistant Bacteria and Eukaryotic Parasites (R01)
Letters of Intent Receipt Date: August 24, 2009
Application Due Date: November 9, 2009
Focus: To support translational research applications for projects that will lead to development of therapeutics or medical diagnostics for drug-resistant NIAID Category A, B or C bacteria and eukaryotic parasites. Additionally, applications are invited for development of diagnostics or broad-spectrum therapeutics against non-listed bacteria and eukaryotic parasites for which naturally-occurring drug resistance is a significant and/or rapidly growing clinical problem.
Contact Info
Dr. Suman Mukhopadhyay
E-mail: mukhopadhyays@mail.nih.gov
Dr. Michael Schaefer
E-mail: mschaefer@niaid.nih.gov
Partnerships for Development of Therapeutics and Diagnostics for Drug-Resistant Bacteria and Eukaryotic Parasites (SBIR [R43/R44])Letters of Intent Receipt Date: October 9, 2009
Application Due Date: November 9, 2009
Focus: To support translational research applications for projects that will lead to development of therapeutics or medical diagnostics for drug-resistant NIAID Category A, B or C bacteria and eukaryotic parasites. Additionally, applications are invited for development of diagnostics or broad-spectrum therapeutics against non-listed bacteria and eukaryotic parasites for which naturally-occurring drug resistance is a significant and/or rapidly growing clinical problem.
Contact Info
Scientific Research Questions:
Dr. Michael Schaefer
E-mail: mschaefer@niaid.nih.gov
NIAID SBIR/STTR Program Questions:
Dr. Gregory Milman
E-mail: gmilman@niaid.nih.gov
High-Priority Influenza Research Areas
Focus: Research aimed at developing tools to control epidemic influenza and the increasing threat of pandemic influenza is one of NIAID's highest priorities. Areas of high priority include, but are not limited to, the following:
- Development of improved drugs against influenza, including structure/function studies of influenza virus proteins with the goal of identifying new therapeutic targets.
- The development of novel influenza vaccines and vaccination strategies. Novel approaches might include developing and evaluating new vaccine formulations, adjuvants, immune response stimulators, protective T-cell and antibody epitopes, new routes of delivery, common epitope vaccines, and alternatives to egg-based vaccine production technologies.
- The development of sensitive, specific, and rapid clinical diagnostic tests for influenza.
- Evaluation of the immune response to infection and/or vaccination including cell-mediated and innate immunity.
- Determination of the molecular basis of virulence of influenza viruses in humans and animals.
- Evaluation of the molecular and/or environmental factors that influence the transmission of influenza viruses, including drug-resistant strains.
- Studies on the evolution and emergence of influenza viruses, including the identification of factors that affect influenza host-range and virulence.
- Virologic and serologic surveillance studies of the distribution of influenza viruses with pandemic potential in animal populations and in humans at the human/animal interface.
Standard Receipt Dates
The goal of this program announcement (PA) is to invite Small Business Innovation Research (SBIR) advanced technology projects that require a longer award period and greater award amount than those routinely allowed under the SBIR program, including
- Development of vaccines, biologics, drugs, and prevention strategies for infectious and immunologic diseases, allergy, and transplantation
- Development of vaccine, biologic, and drug delivery systems
- Development of assays and therapeutic monitoring systems for clinical and vaccine trials and for improved diagnosis of infectious, allergic, and immunologic diseases
Contact Info
Scientific/research issues: Gregory Milman
E-mail: gm16s@nih.gov
Financial/grants management matters: Pamela Fleming
E-mail: pf49e@nih.gov
This funding opportunity announcement (FOA) solicits Small Business Technology Transfer Research (STTR) grant applications from small business concerns (SBCs) for advanced technology projects that require a longer award period and greater award amount than those routinely allowed under the STTR program, including:
- A vaccine, biologic, or drug to treat an infectious disease, an immunologic disease, allergy, or transplantation.
- A vaccine, biologic or drug delivery system.
- Assays for the diagnosis of an infectious disease, immunologic disease, allergic disease, or as an aid to transplantation, or therapeutic monitoring systems for clinical trials of vaccines, biologics, drugs or transplantation.
Contact Info
Scientific/research issues: Gregory Milman
E-mail: gm16s@nih.gov
Financial/grants management matters: Pamela Fleming
E-mail: pf49e@nih.gov
back to top